MCID: ABD014
MIFTS: 59

Abdominal Obesity-Metabolic Syndrome 1

Categories: Metabolic diseases, Genetic diseases

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 57 12
Metabolic Syndrome X 57 12 76 29 55 15 40 73
Metabolic Syndrome 44 63
Abdominal Obesity Metabolic Syndrome 73
Dysmetabolic Syndrome X 12
Aoms1 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
abdominal obesity-metabolic syndrome 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 605552
Disease Ontology 12 DOID:14221
ICD10 33 E88.81
ICD9CM 35 277.7
MeSH 44 D024821
NCIt 50 C84442
SNOMED-CT 68 190394009 237602007
MedGen 42 C2930930

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM : 57 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552)

MalaCards based summary : Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to abdominal obesity-metabolic syndrome quantitative trait locus 2 and abdominal obesity-metabolic syndrome 3, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MEG3 (Maternally Expressed 3
Pioglitazone up-regulated MEG3 expression to protect EPCs via decreasing miR-140-5p expression and increasing HDAC7 expression in MetS, which may be a novel therapeutic target for preventing and treating MetS.
Dysfunction Pattern: Expression), and among its related pathways/superpathways are Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Ezetimibe and Simvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and endothelial, and related phenotypes are hypertension and abdominal obesity

PubMed Health : 63 About metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke.The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease.In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries.Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Wikipedia : 76 Metabolic syndrome, sometimes known by other names, is a clustering of at least three of the five... more...

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 abdominal obesity-metabolic syndrome quantitative trait locus 2 31.2 AOMS1 INS LEP SLC2A4
2 abdominal obesity-metabolic syndrome 3 12.1
3 lipodystrophy, familial partial, type 2 10.3 INS LEP
4 pituitary-dependent cushing's disease 10.2 HSD11B1 INS
5 fetal macrosomia 10.2 INS LEP
6 congenital generalized lipodystrophy 10.2 INS LEP
7 intracranial hypertension 10.1 HSD11B1 SERPINE1
8 alstrom syndrome 10.1 INS LEP
9 cerebrovascular disease 10.0 INS MEG3 SERPINE1
10 pancreas disease 10.0 INS LEP
11 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.9 ADIPOQ INS
12 diabetes mellitus, insulin-dependent 9.8 INS LEP MEG3
13 acquired generalized lipodystrophy 9.8 ADIPOQ LEP
14 obesity-hypoventilation syndrome 9.8 ADIPOQ LEP
15 anovulation 9.8 INS LEP
16 hyperinsulinism 9.8 INS LEP SERPINE1
17 idiopathic recurrent pericarditis 9.8 ADIPOQ LEP
18 familial partial lipodystrophy 9.7 INS LEP PPARG
19 nontuberculous mycobacterial lung disease 9.7 ADIPOQ LEP
20 coronary artery aneurysm 9.6 ADIPOQ LEP
21 nonalcoholic steatohepatitis 9.4 ADIPOQ INS LEP
22 idiopathic edema 9.4 ADIPOQ INS PPARG
23 apnea, obstructive sleep 9.4 ADIPOQ INS LEP
24 inherited metabolic disorder 9.4 ADIPOQ INS LEP
25 sleep apnea 9.3 ADIPOQ INS LEP
26 chronic kidney failure 9.3 ADIPOQ INS LEP
27 prader-willi syndrome 9.2 ADIPOQ INS LEP
28 osteoporosis 9.1 HSD11B1 INS LEP PPARG
29 coronary artery anomaly 9.1 ADIPOQ INS SERPINE1
30 coronary heart disease 1 9.1 ADIPOQ INS MTTP SERPINE1
31 liver disease 9.0 ADIPOQ INS LEP MEG3
32 severe pre-eclampsia 9.0 ADIPOQ LEP
33 atherosclerosis susceptibility 8.8 ADIPOQ INS PPARG SERPINE1
34 arteriosclerosis 8.8 ADIPOQ INS PPARG SERPINE1
35 hypertension, essential 8.8 ADIPOQ INS LEP SERPINE1
36 prediabetes syndrome 8.8 ADIPOQ INS LEP PPARG
37 pre-eclampsia 8.8 ADIPOQ LEP SERPINE1
38 vascular disease 8.8 ADIPOQ INS PPARG SERPINE1
39 acanthosis nigricans 8.8 ADIPOQ INS LEP PPARG
40 3-hydroxyacyl-coa dehydrogenase deficiency 8.8 ADIPOQ INS LEP PPARG
41 morbid obesity 8.8 ADIPOQ INS LEP PPARG
42 hyperglycemia 8.8 ADIPOQ INS LEP PPARG
43 endocrine pancreas disease 8.7 ADIPOQ INS LEP SLC2A4
44 glucose intolerance 8.7 ADIPOQ INS LEP SLC2A4
45 gestational diabetes 8.7 ADIPOQ INS LEP SLC2A4
46 fatty liver disease 8.4 ADIPOQ INS LEP MTTP PPARG
47 arteries, anomalies of 8.3 ADIPOQ INS LEP PPARG SERPINE1
48 lipid metabolism disorder 7.9 ADIPOQ INS LEP MTTP PPARG SERPINE1
49 glucose metabolism disease 7.5 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4
50 acquired metabolic disease 7.5 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Symptoms via clinical synopsis from OMIM:

57
Growth Weight:
abdominal obesity

Laboratory Abnormalities:
elevated fasting glucose levels

Cardiovascular Vascular:
hypertension


Clinical features from OMIM:

605552

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

32
# Description HPO Frequency HPO Source Accession
1 hypertension 32 HP:0000822
2 abdominal obesity 32 HP:0012743

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.08 ADIPOQ HSD11B1 INS LEP MTTP PPARG
2 adipose tissue MP:0005375 10.04 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
3 growth/size/body region MP:0005378 10.03 ADIPOQ HSD11B1 INS LEP MTTP PPARG
4 homeostasis/metabolism MP:0005376 9.97 ADIPOQ HSD11B1 INS LEP MTTP PPARG
5 hematopoietic system MP:0005397 9.95 PPARG SERPINE1 ADIPOQ HSD11B1 INS LEP
6 endocrine/exocrine gland MP:0005379 9.93 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
7 immune system MP:0005387 9.87 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
8 liver/biliary system MP:0005370 9.76 ADIPOQ HSD11B1 INS LEP MTTP PPARG
9 integument MP:0010771 9.73 ADIPOQ HSD11B1 INS LEP PPARG SERPINE1
10 muscle MP:0005369 9.43 ADIPOQ HSD11B1 INS LEP PPARG SLC2A4
11 renal/urinary system MP:0005367 9.02 ADIPOQ INS LEP PPARG SERPINE1

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

PubMedHealth treatment related to Abdominal Obesity-Metabolic Syndrome 1: 63

Healthy lifestyle changes are the first line of treatment for metabolic syndrome. Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking.If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure, high triglycerides, low HDL cholesterol, and high blood sugar.Blood-thinning medicines, such as aspirin, also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome.

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 744)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4,Phase 3,Not Applicable 163222-33-1 150311
2
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
3
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
4
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
5
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
6
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1 137862-53-4 60846
7
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
8
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
9
Spironolactone Approved Phase 4,Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
10
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
11
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
12
Orlistat Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 96829-58-2 3034010
13
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0 6013
15
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
16
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
17
Amlodipine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 88150-42-9 2162
18
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
19
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 129722-12-9 60795
20
Losartan Approved Phase 4,Phase 3,Phase 2,Not Applicable 114798-26-4 3961
21
Olmesartan Approved, Investigational Phase 4,Phase 3 144689-24-7, 144689-63-4 158781 130881
22
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 111025-46-8 4829
23
Zinc Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
24
Cyproterone Acetate Approved, Investigational Phase 4,Not Applicable 427-51-0
25
Ethinyl Estradiol Approved Phase 4,Phase 2,Not Applicable 57-63-6 5991
26
Ethanol Approved Phase 4,Phase 3,Not Applicable 64-17-5 702
27
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
28
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
29
Curcumin Approved, Investigational Phase 4,Phase 2,Not Applicable 458-37-7 969516
30
Clozapine Approved Phase 4,Phase 2,Not Applicable 5786-21-0 2818
31
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
32
Haloperidol Approved Phase 4,Not Applicable 52-86-8 3559
33
Irbesartan Approved, Investigational Phase 4,Not Applicable 138402-11-6 3749
34
Histamine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 75614-87-8, 51-45-6 774
35
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 146939-27-7 60854
36
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
37
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Not Applicable 49562-28-9 3339
38
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 132539-06-1 4585
39
Risperidone Approved, Investigational Phase 4,Phase 3,Not Applicable 106266-06-2 5073
40
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
41
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
42
Allopurinol Approved Phase 4,Phase 2,Not Applicable 315-30-0 2094
43
Magnesium oxide Approved Phase 4,Phase 3,Phase 2 1309-48-4 14792
44
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
45
Iron Approved Phase 4,Not Applicable 7439-89-6 23925
46
Galantamine Approved Phase 4 357-70-0 9651
47 Titanium dioxide Approved Phase 4,Phase 3,Phase 2 13463-67-7
48
Clopidogrel Approved Phase 4,Not Applicable 120202-66-6, 113665-84-2 60606
49
Ticlopidine Approved Phase 4 55142-85-3 5472
50
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 1874)
# Name Status NCT ID Phase Drugs
1 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. Unknown status NCT00988364 Phase 4 Simvastatin;Vytorin;Placebo;Ezetimibe
2 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
3 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
4 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
5 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
6 Metformin in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
7 The ACT-OUT Trial: ACTivity OUTcomes Based on High Carbohydrate or High Fat Diet in Metabolic Syndrome Unknown status NCT01357382 Phase 4
8 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
9 Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) Unknown status NCT00790946 Phase 4 Valsartan
10 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
11 Diurnal Variation of Plasminogen Activator Inhibitor-1 Unknown status NCT00515021 Phase 4 Eplerenone (Morning vs. evening drug regimen)
12 Cortisol and Nutritional Sympathetic Responsiveness Unknown status NCT01620684 Phase 4 metyrapone;placebo
13 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
14 Efficacy and Safety of Lobeglitazone Versus Sitagliptin Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
15 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
16 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
17 The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
18 Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ
19 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
20 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4 pioglitazone
21 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
22 PCOS, Therapy and Markers of Cardiovascular Risk Unknown status NCT01798875 Phase 4 oral metformin;oral contraceptive
23 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
24 A Trial to Study the Effect of Long Term Vitamin D Supplementation on Insulin Sensitivity Unknown status NCT01052181 Phase 4 Cholecalciferol;placebo
25 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
26 Korean AMADEUS Study Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
27 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
28 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
29 Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes Unknown status NCT02236481 Phase 4 Anakinra;TNF alpha inhibitors
30 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4 curcumin
31 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
32 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
33 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
34 The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine Unknown status NCT01654640 Phase 4 Metformin;Placebo (for metformin)
35 Galantamine Effects in Patients With Metabolic Syndrome Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
36 Mesoglycan, Vascular Reactivity and Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Mesoglycan;Placebo;Placebo
37 PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
38 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
39 Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion Completed NCT02113241 Phase 4 Dapagliflozin;Placebo
40 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
41 Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome Completed NCT00640276 Phase 4 pitavastatin
42 The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome Completed NCT00664742 Phase 4 Fluvastatin XL®
43 Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome Completed NCT00138528 Phase 4 Fluvastatin
44 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome Completed NCT00815659 Phase 4 rosuvastatin
45 Irbesartan in the Treatment of Hypertensive Patients With Metabolic Syndrome Completed NCT00110422 Phase 4 Irbesartan;Hydrochlorothiazide
46 Caduet and TLC Intervention in Metabolic Syndrome Completed NCT03504735 Phase 4 Caduet Pill;Placebo
47 The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome Completed NCT00926341 Phase 4 Pioglitazone;Telmisartan
48 Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome Completed NCT00335699 Phase 4 Rosuvastatin
49 Effect of Magnesium Administration in Subjects With Family History of Diabetes or Metabolic Syndrome Completed NCT01181830 Phase 4 magnesium pidolate;placebo
50 The Effects of Cilnidipine on Metabolic Syndrome Improvement Completed NCT00325936 Phase 4 Cilnidipine

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 29 MTTP

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

MalaCards organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

41
Liver, Heart, Endothelial, Ovary, Prostate, Bone, Kidney

Publications for Abdominal Obesity-Metabolic Syndrome 1

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 60)
# Title Authors Year
1
The question of metabolic syndrome X. ( 26631307 )
2015
2
Circulating adipokines and insulin resistance in subjects with combined cardiac and metabolic syndrome X. ( 26413164 )
2015
3
Glycyrrhizin ameliorates insulin resistance, hyperglycemia, dyslipidemia and oxidative stress in fructose-induced metabolic syndrome-X in rat model. ( 23923606 )
2013
4
Central retinal artery occlusion in a patient with metabolic syndrome x. ( 22737328 )
2010
5
Anaesthetic considerations in metabolic syndrome X. ( 20532086 )
2010
6
Beneficial effects of modified egg* on oxidative stress in F1- generation of metabolic syndrome-X induced Wistar rat. ( 19374165 )
2009
7
Cardiac syndrome X versus metabolic syndrome X. ( 17010457 )
2007
8
Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? ( 17475465 )
2007
9
[The metabolic syndrome X or insulin resistance syndrome]. ( 17304724 )
2007
10
Aberrant expression of perilipins and 11-beta-HSD-1 as molecular signatures of metabolic syndrome X in south east Asians. ( 16941796 )
2006
11
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. ( 16416266 )
2006
12
Long term excessive Zn-supplementation promotes metabolic syndrome-X in Wistar rats fed sucrose and fat rich semisynthetic diet. ( 16999025 )
2006
13
Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 15833894 )
2005
14
A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. ( 15734832 )
2005
15
Pathophysiology of metabolic syndrome X and its links to the perinatal period. ( 15925303 )
2005
16
Swiss Medical Weekly Young Investigator's Award 2003: Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 15243846 )
2004
17
Metabolic syndrome X: an inflammatory condition? ( 14972097 )
2004
18
HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure. ( 15470277 )
2004
19
Low-flow vascular remodeling in the metabolic syndrome X. ( 14644764 )
2004
20
Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. ( 12697574 )
2003
21
Pathobiology of metabolic syndrome X in obese and non-obese South Asian Indians: further discussion and some suggestions. ( 12781862 )
2003
22
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( 15028595 )
2003
23
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( 12756274 )
2003
24
The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. ( 12946657 )
2003
25
Longitudinal changes in risk variables underlying metabolic Syndrome X from childhood to young adulthood in female subjects with a history of early menarche: the Bogalusa Heart Study. ( 14574352 )
2003
26
Metabolic syndrome X is common in Indians: but, why and how? ( 14719590 )
2003
27
Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X. ( 12537988 )
2003
28
Clustering of cardiovascular risk factors mimicking the human metabolic syndrome X in eNOS null mice. ( 12947532 )
2003
29
Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. ( 11856814 )
2002
30
The metabolic syndrome X and peripheral cortisol synthesis. ( 12397528 )
2002
31
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X. ( 12512799 )
2002
32
Is metabolic syndrome X an inflammatory condition? ( 12486208 )
2002
33
Obesity, metabolic syndrome X, and inflammation. ( 11985951 )
2002
34
Metabolic syndrome X--high risk factor for acute myocardial infarction and its complications. ( 12137304 )
2002
35
Metabolic syndrome X is common in South Asians, but why and how? ( 12297221 )
2002
36
Molecular mechanism of vascular disease in metabolic syndrome X. ( 11872360 )
2002
37
Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy. ( 11958275 )
2001
38
Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity. ( 15573024 )
2001
39
Unravelling metabolic syndrome X. ( 11427370 )
2001
40
Steroid metabolism in metabolic syndrome X. ( 11469814 )
2001
41
Insulin resistance: the metabolic syndrome X ( 10713753 )
2000
42
Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. ( 11057441 )
2000
43
Metabolic syndrome X: a review. ( 10863169 )
2000
44
Metabolic syndrome X and fibrinolytic disturbances. ( 10870268 )
2000
45
Liver pathology and the metabolic syndrome X in severe obesity. ( 10323371 )
1999
46
Hypothalamic origin of the metabolic syndrome X. ( 10842670 )
1999
47
The metabolic syndrome X. ( 10842649 )
1999
48
Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X. ( 10483984 )
1999
49
Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. ( 10842660 )
1999
50
Correlation of fasting serum C-peptide and insulin with markers of metabolic syndrome-X in a homogenous Chinese population with normal glucose tolerance. ( 10189006 )
1999

Variations for Abdominal Obesity-Metabolic Syndrome 1

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.6 ADIPOQ LEP PPARG SLC2A4
2
Show member pathways
12.58 ADIPOQ INS LEP SLC2A4
3 12.2 ADIPOQ INS PPARG SLC2A4
4
Show member pathways
12.07 ADIPOQ INS LEP PPARG SLC2A4
5
Show member pathways
11.91 INS LEP SLC2A4
7
Show member pathways
11.83 ADIPOQ INS PPARG
8
Show member pathways
11.59 ADIPOQ INS SLC2A4
9 11.38 ADIPOQ LEP SLC2A4
10 11.28 LEP SLC2A4
11 11.26 INS LEP
12 11.22 ADIPOQ INS LEP PPARG SERPINE1 SLC2A4
13 11.19 INS SLC2A4
14 11 INS SLC2A4
15 10.9 ADIPOQ LEP PPARG
16 10.66 INS SLC2A4
17 10.6 ADIPOQ LEP PPARG SLC2A4

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.87 HSD11B1 LEP MTTP PPARG
2 regulation of signaling receptor activity GO:0010469 9.83 ADIPOQ INS LEP SERPINE1
3 fatty acid beta-oxidation GO:0006635 9.62 ADIPOQ LEP
4 placenta development GO:0001890 9.61 LEP PPARG
5 response to activity GO:0014823 9.61 ADIPOQ LEP
6 response to ethanol GO:0045471 9.61 ADIPOQ LEP SLC2A4
7 positive regulation of glucose import GO:0046326 9.6 ADIPOQ INS
8 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.59 ADIPOQ PPARG
9 brown fat cell differentiation GO:0050873 9.58 ADIPOQ SLC2A4
10 positive regulation of interleukin-8 production GO:0032757 9.58 ADIPOQ SERPINE1
11 cellular response to insulin stimulus GO:0032869 9.58 ADIPOQ PPARG SLC2A4
12 lipoprotein transport GO:0042953 9.56 MTTP PPARG
13 positive regulation of cellular protein metabolic process GO:0032270 9.55 ADIPOQ INS
14 positive regulation of insulin receptor signaling pathway GO:0046628 9.54 INS LEP
15 response to nutrient GO:0007584 9.54 ADIPOQ LEP PPARG
16 regulation of fat cell differentiation GO:0045598 9.51 LEP PPARG
17 fatty acid oxidation GO:0019395 9.49 ADIPOQ PPARG
18 negative regulation of gluconeogenesis GO:0045721 9.48 ADIPOQ INS
19 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.46 ADIPOQ PPARG
20 glucose metabolic process GO:0006006 9.43 ADIPOQ INS LEP
21 response to nutrient levels GO:0031667 9.33 ADIPOQ INS LEP
22 negative regulation of acute inflammatory response GO:0002674 9.32 INS PPARG
23 circadian rhythm GO:0007623 9.26 ADIPOQ LEP MTTP SERPINE1
24 glucose homeostasis GO:0042593 9.02 ADIPOQ INS LEP PPARG SLC2A4

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 ADIPOQ INS LEP

Sources for Abdominal Obesity-Metabolic Syndrome 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....